Zoetis Wins Emergency Authorization for Simparica Trio, Can It Support a Slowing U.S. Business?
News Source : Yahoo Entertainment
News Summary
- Zoetis Inc.'s (NYSE: ZTS ) latest regulatory win is particularly relevant for shareholders.
- Just one week after the animal-health company reported a 7% decline in u.s. revenue and an 11% drop in domestic companion-animal product sales, Simparica Trio received Emergency Use Authorization to treat New World screwworm infestations in dogs and puppies.
- However, investors should keep the development in perspective.
- The authorization is temporary, applies only to treatment and comes without financial benefits.
The timing of Zoetis Inc.s (NYSEZTS) latest regulatory win is particularly relevant for shareholders. Just one week after the animalhealth company reported a 7% decline in U.S.
Never miss a story from us, subscribe to our newsletter